Bioventus Inc.

Bioventus amended its agreement to acquire CartiHeal, reducing the closing payment to $50 million and deferring $215 million into tranches, with the acquisition expected to close by end of July 2022.

Bioventus Inc. exercised its call option to acquire CartiHeal Ltd. for approximately $315 million, with an additional $135 million contingent on sales milestones, following FDA approval of CartiHeal's Agili-C implant.

Bioventus will invest $9.1 million and create 40 new jobs in Cordova, Tennessee, expanding its existing operations in Shelby County to meet growing customer demands.

Misonix, a provider of minimally invasive therapeutic ultrasonic technologies, has been acquired by Bioventus. Misonix stockholders received either 1.6839 shares of Bioventus class A common stock or $28.00 in cash per share.

Bioventus has made a $50 million escrow payment signaling its intent to acquire Israeli medtech company CartiHeal for approximately $500 million, pending FDA approval of CartiHeal's Agili-C implant.

Bioventus will acquire Misonix in a cash-and-stock transaction valued at approximately $518 million, adding minimally invasive ultrasonic technologies and regenerative medicine products.

Bioventus Inc. acquired Bioness Inc., a rehabilitation solutions company, for $45 million up-front with up to $65 million contingent on milestones.